The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice
PLOS One · 2025
DOI: 10.1371/journal.pone.0323550 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Mayuko Takezaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Georgia Cancer Center, Augusta University, Augusta, Georgia. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Fetal Hemoglobin, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI Division of Intramural Research.
Abstract (Originalsprache)
The most common hemoglobin disorder worldwide is sickle cell disease (SCD) caused by a point mutation in the adult β-globin gene. As a result, hemoglobin S production occurs leading to clinical symptoms including vaso-occlusive pain, organ damage, and a shortened lifespan. Hydroxyurea is the only FDA-approved fetal hemoglobin (HbF) inducer in the United States that ameliorates the clinical severity of SCD. Due to challenges with hydroxyurea, our study aimed to address the unmet need for the development of non-chemotherapeutic HbF inducers. We investigated the ability of CT-101, a Class 1 histone deacetylase inhibitor, to flip the γ-globin to β-globin switch in a humanized SCD mouse model. Pharmacokinetic parameters were assessed in CD-1 and Townes SCD mice after a single intraperitoneal drug dose. Similar drug uptake and half-life were observed in both animals. Subsequent studies in β-YAC mice expressing human γ-globin and β-globin genes established the optimal dose of CT-101 that induces HbF without peripheral blood toxicity. Subsequent confirmatory studies were conducted in the SCD mouse treated with intraperitoneal CT-101, demonstrating increases in F-cells, HbF, and γ-globin gene mRNA levels. Hydroxyurea combined with CT-101 significantly decreased spleen size and hemorrhagic infarcts and improved splenic extramedullary hematopoiesis. Our novel agent, CT-101, flipped the switch by activating γ-globin gene transcription and HbF protein synthesis in the preclinical SCD mouse model without significant toxicity in the peripheral blood. These findings support the development of an oral CT-101 formulation for clinical testing in SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Georgia Cancer Center, Augusta University, Augusta, Georgia.
- Department of Biostatistics, Data Science and Epidemiology, Augusta University, Augusta, Georgia.
- Department of Pathology and Laboratory Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia.
- Vascular Biology Center, Department of Pharmacology and Toxicology, Division of Pulmonary and Critical Care Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia.
- Cetya Therapeutics, Fort Collins, Colorado.
- Colorado State University, Department of Chemistry, Fort Collins, Colorado.
ORCID-Profile: Rudolf Lucas, Clifford L Hendrick, Betty S Pace
Förderung
- NHLBI Division of Intramural Research
Zitieren
APA
Takezaki, M., Li, B., Xu, H., Patel, N., Lucas, R., Cerbone, R. E., Koti, S., Hendrick, C. L., Junker, L. H., & Pace, B. S. (2025). The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice. PLOS One. https://doi.org/10.1371/journal.pone.0323550
Vancouver
Takezaki M, Li B, Xu H, Patel N, Lucas R, Cerbone RE, et al. The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice. PLOS One. 2025. doi:10.1371/journal.pone.0323550
BibTeX
@article{Takezaki2025,
author = {Takezaki, Mayuko and Li, Biaoru and Xu, Hongyan and Patel, Nikhil and Lucas, Rudolf and Cerbone, Ryan E and Koti, Sivanagireddy and Hendrick, Clifford L and Junker, Louis H and Pace, Betty S},
title = {The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0323550}
}
EUVIMED